Skip to main content
Premium Trial:

Request an Annual Quote

Xerion Pharmaceuticals Licenses Xoma Ireland Antibody Expression Technology

NEW YORK, Aug. 13 (GenomeWeb News) --  Xerion Pharmaceuticals of Martinsried, Germany, announced today that it has licensed bacterial expression technology developed by Xoma Ireland.

In a statement, Xerion said it will have rights to use Xoma’s antibody expression technology for developing antibody products derived from phage display libraries for itself and its collaborators. The company also has an option to license the production of antibodies under Xoma patents. Xoma will receive license and royalty payments. The two companies also announced a co-development and commercialization option on antibody products generated by Xerion.

Further financial details were not provided.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.